222 results about "Peptide antigen" patented technology

Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the surface of antigen presenting cells, thereby targeting the antigen to the antigen presenting cells in the mammal. In addition, disclosed is a family of adjuvants, for example, an Fc-adjuvant fusion protein, for use in combination with the Fc-antigen fusion proteins to enhance or modulate a particular immune response against the preselected antigen.

Peptide antigens corresponding to amino acid residues 2-12, 1-12, 2-15 and 1-15 of parathyroid hormone (PTH), antibodies having an affinity to such peptide antigens and methods of producing the same. Such antigens, antibodies and methods producing the same according to the present invention are useful in determining bioactive intact PTH levels in serum, plasma, and / or cell culture media. Such antibodies further possess a high degree of species cross-reactivity, but substantially mitigated cross-reactivity to non-whole PTH peptide fragments and little to no recognition of the first amino acid residue of PTH.

The invention relates to a Qbeta-2aa phage virus-like particle protein which is prepared according to a method comprising the following steps of: (1) mutating a Qbeta phage CP (coat protein) gene terminator codon into a strong terminator codon TAA from TGA and then cloning the strong terminator codon into a protokaryon expression vector pET28a(+) to obtain a coding CP plasmid pETQB-CP; (2) inserting the nucleotides AAGCTT of coding lysine and leucine at the coding immunodominance determining region position in a Qbeta phage CP extension protein gene, i.e. between the 72th codon and the 73th codon of the Qbeta phage CP extension protein gene, and mutating the CP gene terminator codon into GGA from TGA and then cloning the GGA into a protokaryon expression vector PGEX4T-2 to obtain a codingA1 protein plasmid pGEXQbeta-A1; (3) jointly converting the mutated coding Qbeta phage CP plasmid and the A1 protein plasmid into escherichia coli, and inducing and then expressing to obtain the virus-like particle protein Qbeta-2aa; and (4) coupling a short peptide antigen to Qbeta-2aa phage virus-like particles by using a iso-bifunctional cross-linking agent.